In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...
In the preceding three months, 12 analysts have released ratings for DexCom (NASDAQ:DXCM), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
DexCom (NASDAQ:DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results